WallStreetZenWallStreetZen

NASDAQ: TXG
10x Genomics Inc Stock

$19.64-0.32 (-1.6%)
Updated Jun 21, 2024
TXG Price
$19.64
Fair Value Price
N/A
Market Cap
$2.35B
52 Week Low
$19.20
52 Week High
$63.57
P/E
-8.81x
P/B
3.27x
P/S
7.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$625.45M
Earnings
-$264.30M
Gross Margin
64.6%
Operating Margin
-41.07%
Profit Margin
-42.3%
Debt to Equity
0.28
Operating Cash Flow
-$27M
Beta
1.27
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TXG Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Zen Score

Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TXG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TXG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TXG is poor value based on its book value relative to its share price (3.27x), compared to the US Health Information Services industry average (2.94x)
P/B vs Industry Valuation
TXG is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TXG due diligence checks available for Premium users.

Be the first to know about important TXG news, forecast changes, insider trades & much more!

TXG News

Valuation

TXG fair value

Fair Value of TXG stock based on Discounted Cash Flow (DCF)
Price
$19.64
Fair Value
-$36.81
Undervalued by
153.36%
TXG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TXG price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.81x
Industry
2.26x
Market
30.75x

TXG price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.27x
Industry
2.94x
TXG is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TXG's financial health

Profit margin

Revenue
$141.0M
Net Income
-$59.9M
Profit Margin
-42.5%
TXG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TXG's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$922.9M
Liabilities
$204.1M
Debt to equity
0.28
TXG's short-term assets ($567.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TXG's short-term assets ($567.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TXG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$15.7M
Investing
$10.6M
Financing
$1.6M
TXG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TXG vs Health Information Service Stocks

TickerMarket Cap1d %P/EP/B
TXG$2.35B-1.60%-8.81x3.27x
PGNY$2.46B+2.05%39.78x4.31x
CERT$2.19B+1.26%-34.97x2.08x
EVH$2.61B+2.13%-17.86x2.13x
PRVA$2.03B+1.19%99.88x3.51x

10x Genomics Stock FAQ

What is 10x Genomics's quote symbol?

(NASDAQ: TXG) 10x Genomics trades on the NASDAQ under the ticker symbol TXG. 10x Genomics stock quotes can also be displayed as NASDAQ: TXG.

If you're new to stock investing, here's how to buy 10x Genomics stock.

What is the 52 week high and low for 10x Genomics (NASDAQ: TXG)?

(NASDAQ: TXG) 10x Genomics's 52-week high was $63.57, and its 52-week low was $19.20. It is currently -69.1% from its 52-week high and 2.29% from its 52-week low.

How much is 10x Genomics stock worth today?

(NASDAQ: TXG) 10x Genomics currently has 119,708,426 outstanding shares. With 10x Genomics stock trading at $19.64 per share, the total value of 10x Genomics stock (market capitalization) is $2.35B.

10x Genomics stock was originally listed at a price of $52.75 in Sep 12, 2019. If you had invested in 10x Genomics stock at $52.75, your return over the last 4 years would have been -62.77%, for an annualized return of -21.89% (not including any dividends or dividend reinvestments).

How much is 10x Genomics's stock price per share?

(NASDAQ: TXG) 10x Genomics stock price per share is $19.64 today (as of Jun 21, 2024).

What is 10x Genomics's Market Cap?

(NASDAQ: TXG) 10x Genomics's market cap is $2.35B, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

10x Genomics's market cap is calculated by multiplying TXG's current stock price of $19.64 by TXG's total outstanding shares of 119,708,426.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.